Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant.
Moore, P.; Moyo, T.; Hermanus, T.; Kgagudi, P.; Ayres, F.; Makhado, Z.; Sadoff, J.; Le Gars, M.; van Roey, G.; Crowther, C.; Garrett, N.; Bekker, L.-G.; Morris, L.; Schuitemaker, H.; Gray, G.
Show abstract
The emergence of SARS-CoV-2 variants, such as 501Y.V2, with immune evasion mutations in the spike has resulted in reduced efficacy of several COVID-19 vaccines. However, the efficacy of the Ad26.COV2.S vaccine, when tested in South Africa after the emergence of 501Y.V2, was not adversely impacted. We therefore assessed the binding and neutralization capacity of n=120 South African sera (from Day 29, post-vaccination) from the Janssen phase 3 study, Ensemble. Spike binding assays using both the Wuhan-1 D614G and 501Y.V2 Spikes showed high levels of cross-reactivity. In contrast, in a subset of 27 sera, we observed significantly reduced neutralization of 501Y.V2 compared to Wuhan-1 D614G, with 22/27 (82%) of sera showing no detectable neutralization of 501Y.V2 at Day 29. These data suggest that even low levels of neutralizing antibodies may contribute to protection from moderate/severe disease. In addition, Fc effector function and T cells may play an important role in protection by this vaccine against 501Y.V2.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine 95%
- Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort 94%
- Durability for 12 months of antibody response to a booster dose of monovalent BNT162b2 in adults who had initially received 2 doses of inactivated vaccine 94%
Similar papers in this journal
- Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccine 95%
- Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including early variants of concern: a test-negative design, British Columbia, Canada 94%
- SARS-CoV-2 evolution and patient immunological history shape the breadth and potency of antibody-mediated immunity 92%
Similar papers in this journal
- Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia 94%
- Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2 93%
- Lower probability and shorter duration of infections after Covid-19 vaccine correlate with anti-SARS-CoV-2 circulating IgGs 93%
Similar papers in this journal
- The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern 95%
- Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination 94%
- Profiling serum immunodominance following SARS-CoV-2 primary and breakthrough infection reveals distinct variant-specific epitope usage and immune imprinting. 94%
Similar papers in this journal
- Strong neutralizing antibody responses to SARS-CoV-2 variants following a single vaccine dose in subjects with previous SARS-CoV-2 infection 95%
- CD8+ T cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants 94%
- Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against 1 JN.1 Subvariants in Adult Participants 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.